Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Novartis and Legend Biotech Sign Exclusive License Agreemen

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Nov 16, 2023 4:57pm

152 Views

Post# 35740089

RE:RE:RE:RE:RE:RE:RE:RE:RE: Novartis and Legend Biotech Sign Exclusive License Agreemen

I am so f***ing pissed off with management for exactly that Azz - great product, but a bunch of girl scouts trying to market it like cookies. NO OFFENSE whatsoever to girl scouts - great product, but all they need to do is smile at you in their uniforms. Maybe that's Andrew's problem - he knocks on BPs door with a big Cheshire Cat grin on his face, or maybe dressing like Oliver Twist with his hands out pleading for more...

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities